Please login to the form below

Not currently logged in
Email:
Password:

neurodegenerative diseases

This page shows the latest neurodegenerative diseases news and features for those working in and with pharma, biotech and healthcare.

Celgene bulks up pipeline again with $2.1bn Prothena deal

Celgene bulks up pipeline again with $2.1bn Prothena deal

Its latest deal gives it a preclinical-stage collaboration focused on targets with potential in neurodegenerative diseases including Alzheimer’s. ... Our collaboration leverages each company’s core expertise in protein homeostasis and protein

Latest news

More from news
Approximately 3 fully matching, plus 46 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... The company has a focus in neurodegenerative diseases and a technology, Antibody Transport Vehicle (ATV) technology, which can enhance blood-brain barrier

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Out-partnering deals included the $1.1bn licence to LEO for tralokinumab in skin diseases and the $1bn divestment to Pfizer of its late-stage small molecule anti-infective business. ... These deals were mainly early stage deals in the areas of

  • Deal Watch December 2016 Deal Watch December 2016

    510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... 320. Evotec (Germany). Celgene (US). Discovery collaboration. Induced pluripotent stem cells for

  • Deal Watch November 2016 Deal Watch November 2016

    equity investment, 2 year collaboration. 145. Chase Pharmaceuticals/ Allergan. fixed dose combinations for Alzheimer's and other neurodegenerative diseases inc CPC-201 (donepezil). ... acquisition - company. 125+. MorphoSys/ Leo Pharma. discovery and

  • Deal Watch February 2016 Deal Watch February 2016

    Pronutria's focus is on the development of therapeutics and nutritional supplements for diseases caused by amino acid imbalances. ... The company is developing oral biologics that deliver disease specific amino acid compositions to restore balance in

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Asceneuron appoints chief medical officer. Novartis’ Michael Ryan joins the neurodegenerative diseases specialist. ... He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience

  • UK Dementia Research Institute names director UK Dementia Research Institute names director

    Prof De Strooper is currently a professor of molecular medicine at the University of Leuven and leads its laboratory for the research of neurodegenerative diseases.

  • Merck’s Michel Vounatsos moves to Biogen Merck’s Michel Vounatsos moves to Biogen

    neurodegenerative and rare diseases around the world. “

  • Nobel laureate Dr Walter Gilbert joins Amylyx Pharmaceuticals Nobel laureate Dr Walter Gilbert joins Amylyx Pharmaceuticals

    The US-based pharmaceutical firm specialises in developing disease-modifying treatments for neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS). ... Loeb University Professor Emeritus at Harvard University. He said: “ Amylyx has

  • CRISPR Therapeutics appoints Dr Tony Coles CRISPR Therapeutics appoints Dr Tony Coles

    He is currently founding investor, chairman and chief executive officer of Yumanity Therapeutics, a biotechnology company focused neurodegenerative diseases. ... novel medicines for patients suffering from diseases with limited treatment options.”.

More from appointments
Approximately 0 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics